Medline Ovid
(exp "pregnancy"/ OR exp "pregnant women"/ OR "pregnancy outcome"/ OR "Pregnancy Complications"/ OR "Puerperal Disorders"/ OR "Postpartum Period"/ OR "Pregnancy, High-Risk"/ OR (pregnan* OR puerper* OR postpartum* OR "post partum*" OR antenatal ).ab,ti.) AND ("Venous Thromboembolism"/ OR "Venous Thrombosis"/ OR * thrombosis/ OR * thromboembolism/ OR (((venous OR vein ) ADJ3 (thrombo*)) OR ((lung OR pulmonar*) ADJ3 embolism*)).ab,ti.) AND ("risk"/ OR "incidence"/ OR "Pregnancy, High-Risk"/ OR (risk OR incidence*).ab,ti.) AND (exp "thrombophilia"/ OR "antithrombins"/ OR "protein S"/ OR "protein C"/ OR "protein C deficiency"/ OR "protein S deficiency"/ OR "prothrombin"/ OR (thrombophil* OR Hypercoagulabilit* OR antithrombin* OR "5 Leiden" OR "V Leiden" OR "protein S" OR "protein C" OR (natural* ADJ3 anticoagulant*) OR prothromb* OR g20210a OR 20201A).ab,ti.) AND ("observational study"/ OR exp "Cohort Studies"/ OR "Epidemiologic Studies"/ OR "Epidemiological Monitoring"/ OR "Case-Control Studies"/ OR "Cross-Sectional Studies"/ OR "multicenter study"/ OR "comparative study"/ OR exp "clinical study"/ OR "Random Allocation"/ OR (((observation* OR epidemiolog* OR famil* OR comparativ*) ADJ6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* ADJ3 (stud* OR survey)) OR ((case OR cases OR match*) ADJ3 control*) OR (cross ADJ section*) OR correlation* OR multicenter* OR (multi* ADJ center*) OR "follow up" OR followup* OR clinical* OR trial OR random*).ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la.
Cochrane
((pregnan* OR puerper* OR postpartum* OR 'post partum*' OR antenatal ):ab,ti) AND ((((venous OR vein ) NEAR/3 (thrombo*)) OR ((lung OR pulmonar*) NEAR/3 embolism*)):ab,ti) AND ((risk OR incidence*):ab,ti) AND ((thrombophil* OR Hypercoagulabilit* OR antithrombin* OR '5 Leiden' OR 'V Leiden' OR 'protein S' OR 'protein C' OR (natural* NEAR/3 anticoagulant*) OR prothromb* OR g20210a OR 20201A):ab,ti)
Web of science
TS=(((pregnan* OR puerper* OR postpartum* OR "post partum*" OR antenatal )) AND ((((venous OR vein ) NEAR/2 (thrombo*)) OR ((lung OR pulmonar*) NEAR/2 embolism*))) AND ((risk OR incidence*)) AND ((thrombophil* OR Hypercoagulabilit* OR antithrombin* OR "5 Leiden" OR "V Leiden" OR "protein S" OR "protein C" OR (natural* NEAR/2 anticoagulant*) OR prothromb* OR g20210a OR 20201A)) AND ((((observation* OR epidemiolog* OR famil* OR comparativ*) NEAR/5 (stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/2 (stud* OR survey)) OR ((case OR cases OR match*) NEAR/2 control*) OR (cross NEAR/1 section*) OR correlation* OR multicenter* OR (multi* NEAR/1 center*) OR "follow up" OR followup* OR clinical* OR trial OR random*))) Google scholar pregnant|pregnancy|puerperal|postpartum "venous|vein thromboembolism|thrombosis"|"lung|pulmonary embolism" risk|incidence thrombophilia|Hypercoagulability|antithrombins|"5|V Leiden"|"protein S|C"|"natural anticoagulants"|prothrombin|g20210a|20201A
List of excluded studies: +  ---+  +  ---7  Simioni   112   2002 cohort  prospective  +  +  ---+  ----9  Tam   113   2012 case-control NA  -+  +  +  -----6  Tormene   114   2001 cohort  retrospective +  +  ---+  +  --+  8 Tormene   115   2007 cohort  retrospective +  +  -----+  --9  Van Boven   116   1999 cohort  retrospective +  +  +  -------8  Vora   117   2007 case-control NA  --+  +  +  ----8  Yilmazer   118   2003 case-control NA  ----+  +  +  --8   Table: Study characteristics Study characteristics of the 43 studies included in the systematic review and meta-analysis: + indicates yes, -indicates no. NA: not applicable. Pregnancies, n refers to the number of pregnancies reported in individual studies, the total number of pregnancies is 41297. NOS score: Newcastle-Ottawa scale assessment score
Appendix Table 2 and 3: Quality assessment of studies. Quality assessment was performed using the Newcastle-Ottawa scale (NOS). It was used for all cohort studies, including those that lack a non-carrier group. As can be appreciated from the items scored, cohort studies that lack a non-carrier group can only get a maximum score of 6.
Appendix Table 2 The question mark in homozygous FVL reflects the following: The probability of antepartum VTE risk being >3% is 47%, and the probability of postpartum risk being >3% is 46%. In family studies the absolute risk estimates are higher than in non-family studies. Due to the limited data no ante-and postpartum analysis could be made for family studies on homozygous FVL could be made. Individual risk factors such as family history, but also other common risk factors for VTE may help guide clinical decision making. 
Results of the individual studies and their meta-analyses

